March Newsletter: Tau Post-Translational Modifications: Therapeutic Targets for Alzheimer’s Disease
- By Cytoskeleton Inc. - Tubulin News
- Apr 6, 2017
Worldwide, more than 47 million people have been diagnosed with dementia, and the majority of these cases are caused by Alzheimer’s disease (AD); aside from the social burden, this neurodegenerative disease has an associated cost of 1.09% of the global gross domestic product. Severe cognitive impairment that leads to deficits in skilled movements, language, and recognition are pathophysiological hallmarks of AD. On a molecular level, neuropathological hallmarks include formation of beta-amyloid plaques and neurofibrillary tangles (NFTs) comprised of paired helical filaments of hyper-phosphorylated Tau proteins. This newsletter focuses on the mechanistic control of Tau by post-translational modifications (PTMs) and the development of novel AD therapeutics based on regulating the PTM status of Tau.
Click to read more
Also included in this newsletter:
- Signal Seeker™ Kits and Pathway Tools, PTM Antibodies, Beads, and more.
- Related Publications